Comparative safety and efficacy of tibolone and escitalopram in postmenopausal women

Background: A high prevalence of psychiatric disorders, particularly depressive and anxiety disorders among women is observed through the postmenopausal stage. Aim: The aim of this study is to compare the safety and efficacy of tibolone (TIB) and escitalopram (ESCIT) in postmenopausal women (PMW). M...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rajnish Raj, Namita Sharma, Rohit Garg, Ekram Goyal
Formato:	article
Lenguaje:	EN
Publicado:	Wolters Kluwer Medknow Publications 2021
Materias:	anxiety postmenopausal depression tibolone Psychiatry RC435-571 Industrial psychology HF5548.7-5548.85
Acceso en línea:	https://doaj.org/article/a7ec4558514f42bdbddf7e513914ad57
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a7ec4558514f42bdbddf7e513914ad57
record_format	dspace
spelling	oai:doaj.org-article:a7ec4558514f42bdbddf7e513914ad572021-11-12T10:11:30ZComparative safety and efficacy of tibolone and escitalopram in postmenopausal women0972-67480976-279510.4103/0972-6748.328805https://doaj.org/article/a7ec4558514f42bdbddf7e513914ad572021-01-01T00:00:00Zhttp://www.industrialpsychiatry.org/article.asp?issn=0972-6748;year=2021;volume=30;issue=3;spage=140;epage=148;aulast=Rajhttps://doaj.org/toc/0972-6748https://doaj.org/toc/0976-2795Background: A high prevalence of psychiatric disorders, particularly depressive and anxiety disorders among women is observed through the postmenopausal stage. Aim: The aim of this study is to compare the safety and efficacy of tibolone (TIB) and escitalopram (ESCIT) in postmenopausal women (PMW). Materials and Methods: It was an interventional, open-label, hospital-based, follow-up study conducted on 60 PMW with the diagnosis of depression as per the Diagnostic and Statistical Manual of Mental Disorder-5 criteria. Patients were divided into two groups of 30 each, i.e. Group I (TIB-2.5 mg/day) and Group II (ESCIT-10–20 mg/day). The primary outcome was assessed for change in climacteric symptom scores on Greene's Climacteric Scale (GCS), severity of depression and anxiety on Hamilton Rating Scale for Depression (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A), and sexual functioning on Arizona Sexual Experience Scale (ASEX). The secondary outcome of well-being was assessed on World Health Organization Quality of life (QOL)-BREF. All the observations were carried out from baseline and at 2, 4, 8, and 12 weeks. Results: Both the groups showed significant improvement in climacteric and depressive symptoms. However, at the 8th and 12th weeks, mean ± standard deviation scores were significantly lower in Group I (GCS score - 24.80 ± 4.92, 20.30 ± 3.56; HAM-D score - 16.57 ± 5.83, 10.2 ± 5.67) compared to Group II (GCS score - 27.27 ± 5.83 and 23.33 ± 5.70, HAM-D score - 19.97 ± 7.98 and 16.17 ± 10.11). No significant difference between the groups was seen for anxiety on HAM-A scores. Only in Group I, there was significant improvement in ASEX scores. QoL in Group I had shown significant improvement in physical and psychological domain compared to Group II at different time interval, i.e. 4th and 8th week onward. In Group I, Alternative Dispute Resolution was reported to be 23.3%, whereas it was 56.7% in Group II. However, none were serious to warrant discontinuation. Conclusion: TIB was better than ESCIT in improving depression, climacteric symptoms, and physical and psychological domain of QoL with an additional benefit of restoring sexual functioning.Rajnish RajNamita SharmaRohit GargEkram GoyalWolters Kluwer Medknow Publicationsarticleanxietypostmenopausal depressiontibolonePsychiatryRC435-571Industrial psychologyHF5548.7-5548.85ENIndustrial Psychiatry Journal, Vol 30, Iss 3, Pp 140-148 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	anxiety postmenopausal depression tibolone Psychiatry RC435-571 Industrial psychology HF5548.7-5548.85
spellingShingle	anxiety postmenopausal depression tibolone Psychiatry RC435-571 Industrial psychology HF5548.7-5548.85 Rajnish Raj Namita Sharma Rohit Garg Ekram Goyal Comparative safety and efficacy of tibolone and escitalopram in postmenopausal women
description	Background: A high prevalence of psychiatric disorders, particularly depressive and anxiety disorders among women is observed through the postmenopausal stage. Aim: The aim of this study is to compare the safety and efficacy of tibolone (TIB) and escitalopram (ESCIT) in postmenopausal women (PMW). Materials and Methods: It was an interventional, open-label, hospital-based, follow-up study conducted on 60 PMW with the diagnosis of depression as per the Diagnostic and Statistical Manual of Mental Disorder-5 criteria. Patients were divided into two groups of 30 each, i.e. Group I (TIB-2.5 mg/day) and Group II (ESCIT-10–20 mg/day). The primary outcome was assessed for change in climacteric symptom scores on Greene's Climacteric Scale (GCS), severity of depression and anxiety on Hamilton Rating Scale for Depression (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A), and sexual functioning on Arizona Sexual Experience Scale (ASEX). The secondary outcome of well-being was assessed on World Health Organization Quality of life (QOL)-BREF. All the observations were carried out from baseline and at 2, 4, 8, and 12 weeks. Results: Both the groups showed significant improvement in climacteric and depressive symptoms. However, at the 8th and 12th weeks, mean ± standard deviation scores were significantly lower in Group I (GCS score - 24.80 ± 4.92, 20.30 ± 3.56; HAM-D score - 16.57 ± 5.83, 10.2 ± 5.67) compared to Group II (GCS score - 27.27 ± 5.83 and 23.33 ± 5.70, HAM-D score - 19.97 ± 7.98 and 16.17 ± 10.11). No significant difference between the groups was seen for anxiety on HAM-A scores. Only in Group I, there was significant improvement in ASEX scores. QoL in Group I had shown significant improvement in physical and psychological domain compared to Group II at different time interval, i.e. 4th and 8th week onward. In Group I, Alternative Dispute Resolution was reported to be 23.3%, whereas it was 56.7% in Group II. However, none were serious to warrant discontinuation. Conclusion: TIB was better than ESCIT in improving depression, climacteric symptoms, and physical and psychological domain of QoL with an additional benefit of restoring sexual functioning.
format	article
author	Rajnish Raj Namita Sharma Rohit Garg Ekram Goyal
author_facet	Rajnish Raj Namita Sharma Rohit Garg Ekram Goyal
author_sort	Rajnish Raj
title	Comparative safety and efficacy of tibolone and escitalopram in postmenopausal women
title_short	Comparative safety and efficacy of tibolone and escitalopram in postmenopausal women
title_full	Comparative safety and efficacy of tibolone and escitalopram in postmenopausal women
title_fullStr	Comparative safety and efficacy of tibolone and escitalopram in postmenopausal women
title_full_unstemmed	Comparative safety and efficacy of tibolone and escitalopram in postmenopausal women
title_sort	comparative safety and efficacy of tibolone and escitalopram in postmenopausal women
publisher	Wolters Kluwer Medknow Publications
publishDate	2021
url	https://doaj.org/article/a7ec4558514f42bdbddf7e513914ad57
work_keys_str_mv	AT rajnishraj comparativesafetyandefficacyoftiboloneandescitalopraminpostmenopausalwomen AT namitasharma comparativesafetyandefficacyoftiboloneandescitalopraminpostmenopausalwomen AT rohitgarg comparativesafetyandefficacyoftiboloneandescitalopraminpostmenopausalwomen AT ekramgoyal comparativesafetyandefficacyoftiboloneandescitalopraminpostmenopausalwomen
_version_	1718431009150599168

Comparative safety and efficacy of tibolone and escitalopram in postmenopausal women

Ejemplares similares